跳至主要内容
临床试验/NCT02653729
NCT02653729已完成2 期

Cognitive Behaviour Therapy for Psychosis in First Episode Patient and the Outcome of Cognitive Behaviour Therapy on Psychotic Symptoms

Aisha Andleeb0 个研究点目标入组 50 人开始时间: 2015年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
50
主要终点
50 participant with schizophrenia assessed by PANSS

研究概览

简要总结

This study aims to examine the effectiveness of cognitive behavior therapy for psychosis in first episode patients and see the outcome of CBT on psychotic symptoms. Because cognitive behavior therapy mostly use in depressive patient to treat the negative thinking pattern Cognitive behavioral approaches in the treatment of psychosis have become more prevalent in recent years for a number of reasons. Evidence has been available for the past two or three decades regarding the success of these techniques with other forms of psychopathology such as depression, anxiety disorders, and medical problems. Anxiety, depression and low self-esteem have been cited as the most common consequences of psychotic disorders. The observation has also emerged that many patients develop their own coping strategies for reducing the frequency, severity, and disruptiveness of their symptoms. There has also been increasing evidence regarding the influence of social environmental factors on the course of psychosis and the development of stress-vulnerability models to explain these relationships. Research suggests that 20 to 50 percent of persons with psychosis who receive neuroleptics continue to experience difficulties related to their psychotic symptoms.

详细描述

This research aims to examine the effect of cognitive and behavior therapy for psychosis in first episode patients and see the outcome of CBT on psychotic symptoms.

Cognitive and Behavior Therapy for Psychosis

Cognitive behavioral therapy (CBT) is talking therapy that can help to manage problems by changing the way you think and behave.

There are notable clinical successes in treating common emotional disorders using cognitive-behavioral approaches based on precise theoretical models. In anxiety disorders, the underlying fear beliefs are tested in behavioral experiments to substantially reduce symptoms; in depression, mood is lifted by reevaluating negative views of the self and limiting excessive rumination.

With psychosis, similar psychological processes are active in the experience of delusions and hallucinations. For example, persecutory delusions are conceptualized as threat beliefs that are the patient's attempts to make sense of his or her personal experiences, while hallucinations are problematic when they are interpreted by the patient as representing powerful and destructive forces. Hence, in cognitive therapy for psychosis, fearful thoughts are carefully reevaluated; withdrawal from social contact and activity is gradually reversed; and feelings of hope, control, and self-worth are fostered. Patients with psychosis are given time to talk about their experiences and, importantly, strategies are developed from this collaborative discussion.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed with psychosis by psychiatrist of the recruiting unit.
  • Patients with duration of illness till 3 years.
  • Patients with the minimum of 5 years of education.
  • Patients within the age range of 18 to 35 years.
  • Competent and willing to give informed consent.
  • Patients living in the study catchment area.

排除标准

  • Patients with drug induced psychosis.
  • Patients with severe psychopathology, unable to give informed consent.
  • Patients suffering from organic or neurological disorder.
  • Patients suffering from chronic physical condition.

研究组 & 干预措施

Espidone, Olepra & Donu

Active Comparator

Espidone tablet 2 mg and Donu 10 mg by mouth twice a day Olepra tablet 5 mg by mouth at night

干预措施: Espidone (Drug)

Espidone, Olepra, Donu & C.B.T

Experimental

Espidone tablet 2 mg and Donu 10 mg by mouth twice a day and Olepra tablet 5 mg by mouth at night and C.B.T 6 session program 45 minutes session after every 15 days

干预措施: cognitive behaviour therapy (Behavioral)

Espidone, Olepra, Donu & C.B.T

Experimental

Espidone tablet 2 mg and Donu 10 mg by mouth twice a day and Olepra tablet 5 mg by mouth at night and C.B.T 6 session program 45 minutes session after every 15 days

干预措施: Espidone (Drug)

Espidone, Olepra, Donu & C.B.T

Experimental

Espidone tablet 2 mg and Donu 10 mg by mouth twice a day and Olepra tablet 5 mg by mouth at night and C.B.T 6 session program 45 minutes session after every 15 days

干预措施: Olepra (Drug)

Espidone, Olepra, Donu & C.B.T

Experimental

Espidone tablet 2 mg and Donu 10 mg by mouth twice a day and Olepra tablet 5 mg by mouth at night and C.B.T 6 session program 45 minutes session after every 15 days

干预措施: Donu (Drug)

Espidone, Olepra & Donu

Active Comparator

Espidone tablet 2 mg and Donu 10 mg by mouth twice a day Olepra tablet 5 mg by mouth at night

干预措施: Olepra (Drug)

Espidone, Olepra & Donu

Active Comparator

Espidone tablet 2 mg and Donu 10 mg by mouth twice a day Olepra tablet 5 mg by mouth at night

干预措施: Donu (Drug)

结局指标

主要结局

50 participant with schizophrenia assessed by PANSS

时间窗: 2 hours

30 item question ask from participant

50 participant with schizophrenia assessed by SAI

时间窗: 30 mintus

three question each have two parts

50 participant with schizophrenia assessed by PSRS

时间窗: 1 hour

6 item on delusion and 11 item on auditory hallucination

次要结局

未报告次要终点

研究者

发起方
Aisha Andleeb
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Aisha Andleeb

M.phil Scholars Department of Applied Psychology

Bahauddin Zakariya University

相似试验